Pharmaceutical Contract Manufacturing Market

Pharmaceutical Contract Manufacturing Market by business segment, Type of API, type of FDF, Type of packaging form, scale of operation, end-users and key geographical regions: Industry Trends and Global Forecasts (3rd Edition), 2021-2035

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    576

  • Pages
    495

  • View Count
    27154

Pharmaceutical Contract Manufacturing Market Overview

The pharmaceutical contract manufacturing market is estimated to be worth $83 billion in 2022 and is expected to grow at CAGR of 6.6% during the forecast period. At present, the pharmaceutical industry is dominated by the presence of small molecule products, which represent close to 80% of the overall pipeline. Even though biologics have shown significant promise in the treatment of a wide range of disorders, in recent years, approval of novel small molecules has been on the rise. In fact, in 2020, over 50 small molecule drugs were approved by the US FDA, while around 8,000 such candidates are being evaluated across different stages of development. It is worth mentioning that the pipeline features increasingly complex candidates, which require specialized facilities, advanced equipment and operational expertise. As setting-up / acquiring manufacturing capabilities is both time and cost intensive process, it is extremely challenging for pharmaceutical companies to perform development and manufacturing operations independently. The aforementioned constraints, coupled to the rising demand for safer and effective drugs (currently driven by the COVID-19 pandemic), have prompted players to outsource a significant portion of their business segments to contract manufacturing organizations (CMOs), and contract development and manufacturing organizations (CDMOs).

The current landscape of pharmaceutical contract service providers is highly fragmented, featuring a mix of start-ups, mid-sized firms and established players. The inherent expertise of CMO manufacturing and CDMOs is believed to be capable of enabling reduction in the time-to-market a product, significant cost-benefits, as well as access to larger production capacities and novel technologies.  It is worth mentioning that there has been substantial merger and acquisition activity in the pharmaceutical contract manufacturing market in the past few years, as players strive to become one stop shops, in order to cater to the diverse needs of pharmaceutical developers (ranging from early-stage development to commercial production). Considering the ongoing innovation in production technologies, evolving pipeline of small molecule products and the increasing demand for such drug candidates, we believe that the pharmaceutical contract manufacturing market is likely to witness positive market growth during the forecast period.

Context of Pharmaceutical Contract Manufacturing Market Opinions and Views of Stakeholders engaged in Pharmaceutical Contract Manufacturing Market List of Pharmaceutical CMOs in Pharmaceutical Contract Manufacturing Market

Key Pharmaceutical Contract Manufacturers in Pharmaceutical Contract Manufacturing Market

Examples of key pharma CMO engaged in pharmaceutical contract manufacturing market (which have also been profiled in this market report; the complete list of CDMO companies is available in the full report) include AMRI Global, Altasciences, Cambrex, Catalent, DPT Laboratories, Thermo Fisher Scientific, Aenova Group, Almac, Corden Pharma, Fresenius Kabi, Glatt, Hovione, Recipharm, Siegfried, CMIC Group, Nectar Lifesciences, Syngene and WuXi AppTec. This market report includes an easily searchable excel database of all the pharmaceutical contract manufacturers, worldwide.

Market Landscape and Market Trends in Pharmaceutical Contract Manufacturing Market Geographical Distribution of Pharmaceutical CMOs in Pharmaceutical Contract Manufacturing Market Recent Expansions in Pharmaceutical Contract Manufacturing Market

Scope of the Report

The “Pharmaceutical Contract Manufacturing Market (3rd Edition) Distribution by key business segments (API(s) and FDF(s)), type of API(s) manufactured (branded and generic), type of FDF(s) offered (oral solids, parenteral and others), type of primary packaging form (blisters, bottles, injectables and others), scale of operation (clinical and commercial), type of end-users (small pharmaceutical companies, mid-sized pharmaceutical companies and large pharmaceutical companies) and key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa: Industry Trends and Global Forecasts, 2021-2035” market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities for the pharmaceutical contract manufacturing market. Amongst the other elements, the market research report features:

  • A detailed overview of the overall market landscape, featuring an elaborate list of over 450 active CMOs engaged in pharmaceutical contract manufacturing market, along with information on several relevant parameters, such as year of establishment, company size, geographical location of CMOs, type of business segment (active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs)), type of API(s) manufactured (complex, generic and sterile), type of FDF(s) offered (oral solids, liquids / semi-solids, injectables, inhalation and others), type of service(s) offered, type of primary packaging form (blister, tubes, vial / cartridge, ampoule, sachets / pouches / bags, inhalers / nasal sprays, glass / plastic / dropper bottles, pre-filled syringes / autoinjectors), scale of operation (preclinical, clinical and commercial) and specific location of manufacturing facilities (country-wise).
  • A detailed analysis of various mergers and acquisitions that have taken place in pharmaceutical contract manufacturing market, highlighting the trend in number of companies acquired and geographical distribution of the activity, during the period 2017-2021. Further, it highlights the relationship between deal multiples (based on revenues), number of employees and experience of the acquired firm. 
  • A detailed analysis of the recent expansions (since 2017) undertaken by various service providers in order to augment their respective pharmaceutical contract manufacturing service portfolios, based on a several relevant parameters, such as year of expansion, purpose of expansion (capability expansion, capacity expansion, facility expansion, new facility), type of business segment (API(s), FDF(s)), capital invested, scale of operation (clinical, commercial), type of service(s) offered (formulation, manufacturing, packaging), geographical location of facility, and most active players (in terms of number of instances).
  • An estimate of the global, installed capacity for the manufacturing of small-molecule drugs, based on information provided by various industry stakeholders in the public domain. It also features distribution of the available capacity on the basis of scale of operation (clinical and commercial), company size (small, mid-sized and large firms) and key geographical regions (North America, Europe and Asia Pacific).
  • Informed estimates of the annual clinical and commercial demand for small molecule drugs, across key geographical regions.
  • A detailed analysis of pharmaceutical contract manufacturing service providers’ capabilities in different regions, based on several relevant parameters, such as type of business segment, type of service(s) offered and type of packaging form.
  • A detailed analysis of various pharmaceutical contract manufacturing service providers featuring schematic representations, including [A] a heat map analysis, highlighting the distribution of integrated contract service providers (companies offering manufacturing services for both small and large molecules), on the basis of  location of their headquarters, year of establishment and number of employees, [B] a geographical landscape analysis, highlighting CMOs that have a wide geographical reach, on the basis of their presence (manufacturing facilities) across various regions, and [C] a grid representation, highlighting the global and regional trend of API and FDF outsourcing services, based on the location of headquarters of the company, number of employees, type of business segment, type of service(s) offered and scale of operation. 
  • A detailed discussion on various guidelines laid down by major regulatory bodies, across different countries, featuring an elaborative assessment of over 450 CMOs engaged in pharmaceutical contract manufacturing market, along with information on their operational approvals, certifications received, and relative popularity of the key regulatory body. Additionally, the chapter features an insightful multi-dimensional bubble analysis, presenting a comparison of the current regulatory scenario in key geographies.
  • Elaborate profiles of key CDMO companies engaged in offering pharmaceutical contract manufacturing services. Each profile features a brief overview of the company, along with information on its financial performance (if available), service(s) portfolio, manufacturing facilities and capabilities, recent developments and an informed future outlook.
  • A case study highlighting a comparison of the key characteristics of large and small molecule drugs, along with information on the steps involved in their respective manufacturing processes.
  • A qualitative analysis highlighting the various factors that need to be taken into consideration by pharmaceutical drug developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
  • A detailed analysis capturing the key parameters and trends that are likely to influence the future of the pharmaceutical contract manufacturing market, under an elaborate SWOT framework. Further, it presents a schematic Harvey ball analysis highlighting the relative impact of each SWOT parameter on the overall pharmaceutical industry.

The key objective of pharmaceutical contract manufacturing market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for pharmaceutical contract manufacturing market during the forecast period. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the forecast period 2021-2035. The market report also features the likely distribution of the opportunity across [A] key business segments (API(s) and FDF(s)), [B] type of API(s) manufactured (branded and generic), [C] type of FDF(s) offered (oral solids, parenteral and others), [D] type of primary packaging form (blisters, bottles, injectables and others), [E] scale of operation (clinical and commercial), [F] type of end-users (small pharmaceutical companies, mid-sized pharmaceutical companies and large pharmaceutical companies) and [G] key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa. In order to account for future uncertainties and add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in pharmaceutical contract manufacturing market. The market report features detailed transcripts of interviews held with the following individuals:

  • Scott Goldstein (Ex - Director, Business Development, Ajinomoto Bio-Pharma Services)
  • Thomas Früh (Ex - CEO, Bachem)
  • Bhaskar Venepalli (President and CEO, CiVentiChem)
  • Roberto Margarita (Director, Business Development, CordenPharma)
  • Allison Vavala (Director, Commercial Development, Helsinn Group)
  • Kevin Daley (Director, Pharmaceuticals Marketing, Novasep)
  • Piyush Desai (Director, Operations, Sovereign Pharma)
  • Ilan Avni (Vice President Business Development, Marketing, and IP, Wavelength Pharmaceuticals)

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this market research report are in USD, unless otherwise specified.

Capacity Analysis in Pharmaceutical Contract Manufacturing Market Demand vs Supply Analysis in Pharmaceutical Contract Manufacturing Market Mergers and Acquisitions Analysis in Pharmaceutical Contract Manufacturing Market

Frequently Asked Questions

Question 1: What is a pharmaceutical contract manufacturing organization?

Answer: A pharma CMO is a special kind of an organization, offering contract manufacturing services to pharmaceutical companies for various kinds of drug components, including small molecules, APIs and excipients.

Question 2: How big is the pharmaceutical contract manufacturing market?

Answer: The pharmaceutical contract manufacturing market size is estimated to be worth $83 billion in 2022.

Question 3: What is the projected market growth of the pharmaceutical contract manufacturing market?

Answer: The pharmaceutical contract manufacturing market is expected to grow at compounded annual growth rate (CAGR) of 6.6% during the forecast period 2021 – 2030.

Question 4: Who are the leading contract manufacturers in the pharmaceutical contract manufacturing market?

Answer: Examples of key contract manufacturers engaged in pharmaceutical contract manufacturing market (which have also been profiled in this market report; the complete list of companies is available in the full report) include AMRI Global, Altasciences, Cambrex, Catalent, DPT Laboratories, Thermo Fisher Scientific, Aenova Group, Almac, Corden Pharma, Fresenius Kabi, Glatt, Hovione, Recipharm, Siegfried, CMIC Group, Nectar Lifesciences, Syngene and WuXi AppTec.

Question 5: How many manufacturers are currently engaged in the pharmaceutical contract manufacturing market?

Answer: Over 490 pharmaceutical contract manufacturers are providing contract manufacturing services for small molecules.

Question 6: How much money has been invested by stakeholders engaged in the pharmaceutical contract manufacturing market?

Answer: Since 2017, over USD 9 billion has been invested by stakeholders engaged in the pharmaceutical contract manufacturing market, for expansion of production facilities.

Question 7: How many partnership deals have been inked between the players engaged in pharmaceutical contract manufacturing market?

Answer: Since 2017, more than 70 partnership deals have been inked between the companies engaged in pharmaceutical contract manufacturing market for the purpose of acquiring or merging with the partner firm.

PRICING DETAILS

USD 4,799

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
click for sending an email to Roots Analysis team sales@rootsanalysis.com